Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Epizyme Reports Business Progress and Second Quarter 2020 Financial Results


Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported second quarter 2020 financial results.

"With back-to-back FDA approvals for TAZVERIK over the course of the last six months, we have a significant opportunity to provide a safe and effective new therapeutic option to patients in need," said Robert Bazemore, president and chief executive officer of Epizyme. "As we move into the second half of the year, we are focused on the successful execution of our launches and all other aspects of our business. Despite the evolving COVID-19 situation, our commercial launches are proceeding very well, and our in-house and clinical collaboration efforts to evaluate tazemetostat in additional combinations and indications remain on track. We have delivered on the major corporate objectives we set for the first half of 2020, and we look forward to the continued advancement of our programs in order to help as many patients as possible."

Recent Progress

Financial Guidance

Based on its current operating plans, Epizyme continues to believe that its existing cash, cash equivalents and marketable securities will fund the company's operations into at least 2022. The company expects its non-GAAP adjusted cash-based operating expenses for 2020 will be between $235 and $255 million, which excludes any milestone payments paid by the company and non-cash items, such as stock-based compensation and amortization or depreciation of intangibles.

Second Quarter 2020 Financial Results

A reconciliation of cash-based financial measures directly comparable to GAAP financial measures is presented in the table attached to this press release.

Conference Call Information
Epizyme will host a conference call today, August 4, at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5081295. A webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call.

About Non-GAAP Financial Measures
In addition to financial information prepared in accordance with the U.S. generally accepted accounting principles (GAAP), this press release includes the following non-GAAP financial measures: total non-GAAP adjusted operating expenses on a historical and projected basis, non-GAAP R&D expenses on a historical basis and non-GAAP SG&A expenses on a historical basis. Epizyme derives these non-GAAP financial measures by excluding certain expenses and other items from the respective GAAP financial measure, that is most directly comparable to each non-GAAP financial measure. Specifically, the non-GAAP financial measures exclude stock-based compensation expense, amortization or depreciation of intangibles and milestone payments related to TAZVERIK that are payable under the company's collaboration agreement with Eisai Pharmaceuticals. The company's management believes that these non-GAAP financial measures are useful to both management and investors in analyzing its ongoing business and operating performance. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP, but as a complement to provide greater transparency. In addition, these non-GAAP financial measures may differ from similarly named measures used by other companies. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to the company's inability to predict with reasonable certainty the amount of future stock-based compensation expense.

About TAZVERIK
TAZVERIK is a methyltransferase inhibitor indicated for the treatment of:

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The most common (?20%) adverse reactions in patients with epithelioid sarcoma are pain, fatigue, nausea, decreased appetite, vomiting and constipation. The most common (?20%) adverse reactions in patients with follicular lymphoma are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea and abdominal pain.

View the U.S. Full Prescribing Information here: Epizyme.com

About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the successful launch of commercial sales of TAZVERIK for epithelioid sarcoma and follicular lymphoma in the approved indications; whether tazemetostat will receive marketing approval for epithelioid sarcoma or follicular lymphoma in other jurisdictions, full approval in the United States or approval in any other indication; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials, such as the ongoing confirmatory trials; whether results from clinical studies will warrant meetings with regulatory authorities, submissions for regulatory approval or review by governmental authorities under the accelerated approval process; expectations for regulatory approvals, including accelerated approval, to conduct trials or to market products; the impact of the COVID-19 pandemic on the company's business, results of operations and financial condition; whether the company's cash resources will be sufficient to fund the company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial success of tazemetostat or the company's therapeutic candidates; and other factors discussed in the "Risk Factors" section of the company's most recent Form 10-Q filed with the SEC and in the company's other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

TAZVERIK® is a registered trademark of Epizyme, Inc.

EPIZYME, INC
CONSOLIDATED BALANCE SHEET DATA (UNAUDITED)
(Amounts in thousands)

 
 

June 30,
2020

December 31,
2019

Consolidated Balance Sheet Data:

Cash and cash equivalents

$

117,152

$

139,482

Marketable securities

 

204,910

 

241,605

Intangible assets, net

 

49,079

 

-

Total assets

 

427,383

 

424,589

Total current liabilities

 

30,655

 

34,386

Deferred revenue

 

3,933

 

3,806

Long-term debt, net of debt discount

 

68,464

 

23,309

Liability related to sale of future royalties

 

13,388

 

12,793

Total stockholders' equity

 

293,363

 

331,137

EPIZYME, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands except per share data)

 

 

Three Months Ended
June 30

Six Months Ended
June 30

 

Three Months Ended
March 31

 

2020

2019

2020

2019

 

2020

Revenues

 

 

Product revenue, net

 

$

2,234

 

$

-

 

$

3,519

 

$

-

 

 

$

1,284

 

Collaboration revenue

 

 

233

 

 

5,900

 

 

303

 

 

13,791

 

 

 

70

 

Total revenue

 

 

2,467

 

 

5,900

 

 

3,822

 

 

13,791

 

 

 

1,354

 

 

 

 

 

 

 

Operating expenses

 

 

 

Cost of product revenue

 

 

1,022

 

 

-

 

 

1,637

 

 

-

 

 

 

614

 

Research and development

 

 

26,352

 

 

40,907

 

 

51,516

 

 

67,803

 

 

 

25,163

 

Selling, general and administrative

 

 

32,659

 

 

15,698

 

 

59,584

 

 

27,684

 

 

 

26,927

 

Total operating expenses

 

 

60,033

 

 

56,605

 

 

112,737

 

 

95,487

 

 

 

52,704

 

Operating loss

 

 

(57,566

)

 

(50,705

)

 

(108,915

)

 

(81,696

)

 

 

(51,350

)

Other income, net:

 

 

 

Interest (expense) income, net

 

 

(569

)

 

2,253

 

 

187

 

 

3,911

 

 

 

756

 

Other expense, net

 

 

(15

)

 

(13

)

 

(64

)

 

(19

)

 

 

(48

)

Non-cash interest expense related to sale of future

royalties

 

 

(301

)

 

-

 

 

(596

)

 

-

 

 

 

(295

)

Other (expense) income, net:

 

 

(885

)

 

2,240

 

 

(473

)

 

3,892

 

 

 

413

 

Loss before income taxes

 

 

(58,451

)

 

(48,465

)

 

(109,388

)

 

(77,804

)

 

 

(50,937

)

Income provision

 

 

-

 

 

-

 

 

-

 

 

-

 

 

 

-

 

Net loss

 

$

(58,451

)

$

(48,465

)

$

(109,388

)

$

(77,804

)

 

$

(50,937

)

 

 

 

 

 

 

Reconciliation of net loss to net loss attributable to common stockholders

 

 

 

Net loss

 

$

(58,451

)

$

48,465

)

$

(109,388

)

$

(77,804

)

 

$

(50,937

)

Accretion of convertible preferred stock

 

 

-

 

 

-

 

 

-

 

 

(2,940

)

 

 

-

 

Net loss attributable to common stockholders

 

$

(58,451

)

$

(48,465

)

$

(109,388

)

$

(80,744

)

 

$

(50,937

)

Net loss per share attributable to common stockholders - basic and diluted

 

$

(0.58

)

$

(0.53

)

$

(1.09

)

$

(1.04

)

 

$

(0.51

)

 

 

 

Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted

 

 

101,104

 

 

90,876

 

 

100,360

 

 

77,315

 

 

 

99,616

 

EPIZYME, INC.
Reconciliation of Selected GAAP Measures to Non-GAAP Measures (UNAUDITED)
(Amounts in thousands)

     

 

Three Months Ended
June 30

Six Months Ended
June 30

 

Three Months Ended
March 31

Reconciliation of GAAP to Non-GAAP Cost of Product Revenue

 

2020

2019

 

2020

2019

 

2020

GAAP Cost of Product Revenue

 

$

1,022

 

$

-

 

 

$

1,637

 

$

-

 

 

$

614

 

Less: Depreciation and Amortization

 

 

(623

)

 

-

 

 

 

(921

)

 

-

 

 

 

(298

)

Non-GAAP Cost of Product Revenue

 

$

399

 

$

-

 

 

$

716

 

$

-

 

 

$

316

 

     

 

     

 

Reconciliation of GAAP to Non-GAAP Research and Development

     

 

GAAP Research and Development

 

$

26,352

 

$

40,907

 

 

$

51,516

 

$

67,803

 

 

$

25,163

 

Less: Stock-Based Compensation Expenses

 

 

(2,803

)

 

(1,732

)

 

 

(4,966

)

 

(2,897

)

 

 

(2,162

)

Less: Depreciation and Amortization

 

 

(130

)

 

(157

)

 

 

(268

)

 

(315

)

 

 

(138

)

Less: Eisai R&D Milestone Expense

 

 

-

 

 

(10,000

)

 

 

-

 

 

(10,000

)

 

 

-

 

Non-GAAP Research and Development

 

$

23,419

 

$

29,018

 

 

$

46,282

 

$

54,591

 

 

$

22,863

 

     

 

Reconciliation of GAAP to Non-GAAP Selling, General and Administrative:

     

 

GAAP Selling, General and Administrative

 

$

32,659

 

$

15,698

 

 

$

59,584

 

$

27,684

 

 

$

26,927

 

Less: Stock-Based Compensation Expenses

 

 

(5,488

)

 

(2,996

)

 

 

(9,836

)

 

(5,042

)

 

 

(4,348

)

Less: Depreciation and Amortization

 

 

(100

)

 

(52

)

 

 

(193

)

 

(101

)

 

 

(93

)

Non-GAAP Selling, General and Administrative

 

$

27,071

 

$

12,650

 

 

$

49,555

 

$

22,541

 

 

$

22,486

 

     

 

Reconciliation of GAAP to Non-GAAP Operating Expenses

     

 

GAAP Operating Expenses

 

$

60,033

 

$

56,605

 

 

$

112,737

 

$

95,487

 

 

$

52,704

 

Less: Stock-Based Compensation Expenses

 

 

(8,291

)

 

(4,728

)

 

 

(14,802

)

 

(7,939

)

 

 

(6,510

)

Less: Depreciation and Amortization

 

 

(853

)

 

(209

)

 

 

(1,382

)

 

(416

)

 

 

(529

)

Less: Eisai R&D Milestone Expense

 

 

-

 

 

(10,000

)

 

 

-

 

 

(10,000

)

 

 

-

 

Non-GAAP Operating Expenses

 

$

50,889

 

$

41,668

 

 

$

96,553

 

$

77,132

 

 

$

45,665

 


These press releases may also interest you

at 01:00
Online therapy platform, Talkcircle has today announced free online support for COVID-affected MENA residents, for one week along with additional ongoing discounts for Lebanon residents, affected by the recent explosion. Talkcircle provides coping...

26 sep 2020
Farm Aid marked its 35th anniversary today with Farm Aid 2020 On the Road, a three-and-a-half-hour, virtual at-home festival featuring 22 artists who helped showcase the critical need for family farmers, the food they produce and their care for soil...

26 sep 2020
The Correctional Service of Canada (CSC) is taking additional measures to limit the potential spread of COVID-19 in its Quebec institutions and community correctional centres (CCCs). CSC is suspending visits at all of its sites in the province, as...

26 sep 2020
CPAP Store USA, a leading provider of world's finest CPAP machines, supplies and respiratory products for more than 18 + years, announced today the launch of its own CPAP Store USA brand. The multi-location retail store and the leading online CPAP...

26 sep 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 150,456 cases of COVID-19 in Canada, including 9,255 deaths. The percentage of recovered cases...

26 sep 2020
The most recent data on the evolution of COVID-19 in Québec show 698 new cases, bringing the total number of people infected to 71,005. No new death has occurred in the last 24 hours, but 7 deaths which have occurred between September 19 and...



News published on 4 august 2020 at 06:35 and distributed by: